Lupin gets USFDA nod for generic medication
Topiramate extended-release capsules are indicated for the treatment of seizures in patients six years of age and older.
Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic medication to treat seizures.
The company has received approval from the US Food and Drug Administration (USFDA) to market Topiramate extended-release capsules in the US, the drug firm said in a statement.
The product is a generic equivalent of Supernus Pharmaceuticals, Inc.'s Trokendi XR extended-release capsules, it added.
Topiramate extended-release capsules are indicated for the treatment of seizures in patients six years of age and older.
As per IQVIA MAT, Topiramate extended-release capsules had an estimated annual sale of USD 253 million in the US.
Shares of Lupin ended 1.04 per cent lower at Rs 1,798 apiece on the BSE.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.